Although high-dose chemotherapy and autologous bone marrow transplantation (ABMT) are increasingly being used for the treatment of relapsed and resistant Hodgkin's disease, there have been few large, single-center studies reported with adequate follow-up to allow full evaluation of this therapeutic modality. We present 155 poor-risk Hodgkin's disease patients who received high-dose BEAM (BCNU, etoposide, cytosine arabinoside, and melphalan) chemotherapy and ABMT who have been studied over a period of 8 years. All patients had either not attained a remission on mechlorethamine, vincristine, procarbazine, prednisone-type therapy and had poor prognostic features at presentation, not attained a complete remission or relapsed within 1 year of an initial alternating regimen, or not attained remission with two or more lines of treatment. At the time of ABMT the relapse status of the patients was as follows: 46 patients were primarily refractory to induction therapy, 7 were good partial responders, 52 were in first relapse, 37 in second relapse, and 13 in third relapse. Seventy-eight patients had chemoresistant disease, 33 had chemosensitive disease at the time of ABMT, and 44 were untested for chemosensitivity at latest relapse. The procedure related mortality in the first 90 days post-ABMT of 10% overall. At 3 months 43 patients (28%) were assessed HE MAJORITY of patients with Hodgkin's disease can T be cured by radiotherapy or conventional dosage chemotherapy; approximately 70% of patients are alive 10 years from diagnosis.'.* Outcome is related to clinical stage at presentation, but even some patients with localized disease at presentation will fail to remit or will subsequently relapse.
T be cured by radiotherapy or conventional dosage chemotherapy; approximately 70% of patients are alive 10 years from diagnosis.'.* Outcome is related to clinical stage at presentation, but even some patients with localized disease at presentation will fail to remit or will subsequently relapse.
Relapse does not necessarily indicate a poor outcome. The results of chemotherapy salvage after radiotherapy are as good as chemotherapy given as first-line treatment.3*4 A proportion of patients relapsing from a mechlorethamine, vincristine, procarbazine, and prednisone (M0PP)-type regimen with a remission duration of more than 1 year can be rescued by further MOPP5 or noncross-resistant regimens such as doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Forty-nine such patients treated at the Milan Cancer Institute had a progression-free survival of 55% at 5 years. 6 The use of front-line, alternating noncross-resistant regimens such as MOPP/ABVD or LOPP/EVAP (chlorambucil, vincristine, procarbazine, and prednisone/etoposide, vinblastine, doxorubicin [Adriamycin; Formiktalia Cerlo Erba Ltd, UK], and prednisone) gives better results than MOPP-type therapy but the options for early relapse are more limited. Patients whose disease is primarily refractory to chemotherapy or who relapses after more than one chemotherapy regimen have a poor prognosis. High-dose chemotherapy or total-body irradiation with autologous bone marrow transplantation (ABMT) is now increasingly used in poor-risk patients who have failed conventional therapy, but there have been few large, single-center series reported with adequate follow-up to allow full evaluation of this therapeutic modality. In 1984 we commenced the investigation of high-dose cheas complete responders, 72 patients had a partial response (46%). and 24 patients (1 6%) had no response or progression of disease. However, by 6 months, 53 (24%) patients were assessed as complete responders and 51 (33%) patients had nonprogressive disease. Forty-five patients had received radiotherapy post-ABMT to residual masses (41 patients) or to previous sites of bulk disease (4 patients).
The actuarial overall and progression-free survival at 5 years was 55% and 50%. respectively. On multivariate analysis patients with bulk (masses > 10 cm), heavily pretreated patients (those receiving three or more lines of treatment), and females had a significantly poorer prognosis. Relapse status was also significant for progression-free survival in that patients in second (60%) and third relapse (70%) had a better prognosis than those in first relapse (44%) or with primary refractory disease (33%). Response to prior chemotherapy did not predict for progression-free survival. These results enable comparisons to be made between high-dose chemotherapy with ABMT and conventional dose salvage therapy. Furthermore, although the results as a whole are highly encouraging, certain groups carry an unfavorable prognosis. 0 1993 by The American Society of Hematology. motherapy (BEAM) and ABMT in patients with relapsed or resistant Hodgkin's disease. These patients were selected to have a low chance of long-term survival on the basis of a survival analysis of patients at different stages of their disease registered on the British National Lymphoma Investigation (BNLI) database." Forty-four patients in this study were reported in 1988" and this much larger group is now reported with fuller analysis of prognostic factors and longer followup. The results presented here are highly encouraging and allow informed suggestions to be made for future treatment of similar patients.
MATERIALS AND METHODS

Patient Selection
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Abbreviations: NS, not significant; PFS, progression-free survival; MC, mixed cellularity; LD, lymphocyte depletion; LP, lymphocyte predominance. Includes primary refractory patients.
Group A . Patients with advanced disease who did not attain a complete remission (CR) on MOPP-type chemotherapy if they had either high-grade disease defined as nodular sclerosing grade 11,'' mixed cellularity or lymphocyte deplete disease, or an erythrocyte sedimentation rate (ESR) >59 at presentation.
Patients not attaining a CR or relapsing within 1 year of an initial alternating (MOPP/ABVD, LOPP/EVAP) regimen.
Patients who had treatment failures on two or more lines of treatment.
Group B.
Group C.
Patients presenting with localized disease and treated initially with radiotherapy were considered as above from the time of first subsequent chemotherapy, ie, the initial radiotherapy was not included as a line of treatment. However, radiotherapy administered later after relapse from initial chemotherapy was numbered as a second line of treatment. Each chemotherapy regimen the patient received was counted as a line of treatment. istered after later failure of the induction chemotherapy then became a second line therapy even if it involved the use of the same drugs/ regimens as the initial induction course.
All patients had a Karnofsky score of greater than 70%" at the time of ABMT. All patients had a glomerular filtration rate ofgreater than 60 mL/min as determined by 51Cr EDTA clearance studies,14 and a left ventricle ejection fraction of greater than 40% on a resting gated 9 9 m T~ scan." No patient had bone marrow involvement as assessed by unilateral or bilateral trephine biopsies before bone marrow harvest. This was a criteria for entry into the study. None of the patients were refused high-dose therapy and ABMT if they fulfilled these criteria, but patients may have been preselected in the referral process to our center. Approval was obtained from the Institutional Review Board for these studies. Informed consent was provided according to the Declaration of Helsinki.
Patient Details
Of the 155 patients, there were 99 men and 56 women. There were 9 patients in group A, 26 in group B, and 120 in group C. The median age at the time of ABMT was 29 years (range 14 to 54 years). At initial presentation 4 patients had stage I disease, 62 patients stage 11, 59 patients stage 111, and 30 patients stage IV disease. Ninety-four patients had B symptoms (presence of fever >38"C, night sweats, and/or unexplained loss of 10% or more of body weight) at diagnosis and 63 at ABMT. Thirteen patients had bone marrow involvement and 14 patients had lung involvement at diagnosis. At ABMT, 41 patients had lung involvement and 19 had other stage IV disease.
The patients were a heavily pretreated group, with 18 patients having received a four-drug regimen before ABMT and 78 having received eight drugs administered either sequentially or as an alternating regimen. Fifty-nine patients had received more than eight drugs before ABMT. Table 1 shows the number of lines of treatment received by each patient. Eighty-five patients had received previous local radiotherapy.
At the time of ABMT, 53 patients had .never achieved CR on conventional chemo/radiotherapy, 46 patients were primarily refractory to induction therapy and 7 patients, although not achieving CR, nonetheless had a greater than 75% response to induction therapy and were deemed as good partial responsers. The remaining 102 patients had achieved a remission on previous chemo/ radiotherapy. Fifty-two of 102 patients had proceeded to ABMT at first relapse (22 relapsing within 1 year of MOPP/ABVD-type of therapy and 30 after failing second or even third lines of therapy), 37 patients at second relapse, and 13 patients had three or more relapses before ABMT.
Status at ABMT. Chemosensitivity was assessed according to the response to the latest chemotherapy administered at relapse. Thirty-two patients showed no response or less than 50% response and were classified as resistant relapse. Twenty-six patients showed at least a 50% response and were therefore responding relapsers. However, forty-four patients proceeded to ABMT without receiving conventional salvage therapy at the time of latest relapse (untested relapse) and their chemosensitivity was therefore not known. No patient was excluded on the basis of chemosensitivity testing.
The median length of first remission was 1 I months (2 to 133 months) for those who obtained a remission. First remission was defined as from the time of no disease evidence on clinical examination and computed tomography (CT) scan to the time of first relapse. The patients proceeded to ABMT within a median time of 28 months from diagnosis (6 to 278 months). All patients had radiologic masses at the time of ABMT, although not all were rebiopsied immediately before autografting. It is therefore conceivable that, in a few patients with chemosensitive disease, the radiologic masses may have represented residual fibrosis.
Treatment before ABMT.
Relapse status.
Bone Marrow Harvest
The bone marrow was harvested under general anaesthetic by the normal procedure in our center and cryopreserved as previously described. 16 The dose of bone marrow reinfused exceeded l X IO8 mononuclear cells (MNC)/kg in all cases. Bone marrow cytogenetics were not performed on the harvested bone marrow.
High-Dose Chemotherapy
All patients received BEAM chemotherapy. The first 18 patients received 300 mg/m2 carmustine (BCNU) administered as an infusion over 1 hour on day -6, cytosine arabinoside intravenously 100 mg/ m2 twice a day on days -5 to -2, etoposide 100 mg/m2 once daily on days -5 to -2, and melphalan 140 mg/m2 on day -1. The next 137 patients received the same doses of BCNU and melphalan but the infusions of cytosine arabinoside and etoposide were increased to 200 mg/m2 twice a day on days -5 to -2 and 200 mg/m2 on days -5 to -2, respectively, because there was little nonhematologic toxicity and it was hoped that further dose escalation might increase the antitumor activity. The bone marrow was returned on day 0.
Supportive Therapy
All patients were nursed in single rooms without laminar or filtered air. An indwelling central venous catheter was placed in all patients. None of the patients received prophylactic antibiotics or gastrointestinal tract decontamination.
Response Assessment
To assess response to BEAM and ABMT, patients were reviewed clinically and by CT scan 3 and 6 months following completion of the BEAM therapy. Patients showing no evidence of disease on CT scan were deemed to be in CR. Patients achieving a greater than 50% reduction in tumor mass at the time of assessment were defined as in partial remission at 3 months post-ABMT or as having nonprogressive masses at 6 months. Patients achieving a less than 50% reduction in tumor mass at assessment were defined as nonresponders.
Consolidation Therapy Post-ABMT
Patients were considered for consolidation radiotherapy post-ABMT at 3 months: (1) if there was a residual mass, either clinical or on CT scanning after ABMT; or (2) as consolidation therapy to sites of previous bulk disease, providing radiotherapy was feasible in light of previous treatment and patients had recovered their neutrophil and platelet counts to above 2.0 X 109/L and 100 X 109/L, respectively.
Statistical Analysis
Survival analysis was performed using the method of Kaplan and Meier." Comparison of the survival curves for statistical significance was performed using the log rank test.18 A form of multivariate analysis, proportional hazards regression model, was used to determine the main prognostic factors. Progression-free survival was measured in months from the day of transplantation until disease progression or death from any cause. For the assessment of relapse rate, relapse was defined as disease progression with deaths from procedure-related mortality being censored.
RESULTS
Toxicity and Hematologic Recovery
All 155 patients became severely cytopenic (0.1 < IO X 109/L) after BEAM. The median time to recover to a neutrophil count of > 0.5 X 109/L was 21 Hematologic recovery. days (range 9 to 68), > 50 X 109/L platelets was 30 days (range 13 to 94). Thirteen patients received macrophage colony-stimulating factor (M-CSF); 19 received granulocytemacrophage colony-stimulating factor (GM-CSF); and 14 received granulocyte colony-stimulating factor (G-CSF). M-CSF had no effect on neutrophil recovery but, in a subgroup of patients receiving a bone marrow dose of greater than 2 X 10' MNC/kg, there was accelerated platelet recovery and a lower platelet transfusion requirement." Both GM-CSF and G-CSF accelerated neutrophil recovery to 0.5 X 109/L by 7 days but there was no effect on platelet Early complications (within the first 90 days post-ABMT). All patients had a febrile neutropenic episode (temperature above 38°C for more than 1 hour). Fifty-three patients (34%) had positive blood cultures, 29 with grampositive and 24 with gram-negative organisms. Eleven patients had interstitial pneumonitis (7%), 4 caused by proven aspergillosis, 1 thought to be caused by drug-associated pneumonitis, and 6 from an unknown cause. Eleven patients had severe mucositis (World Health Organization grade 4). Five patients had a toxic enterocolitis, three associated with chemotherapy and two caused by Clostridium d$cile infection. Two patients developed transfusion-associated graft-versushost disease caused by unirradiated blood products. One patient developed a cardiac arrhythmia during the neutropenic phase.
The procedure-related mortality in the first 90 days post-ABMT was 10% overall. There were two early deaths (on days 6 and 7) from toxic enterocolitis caused by chemotherapy. Seven deaths occurred from a proven infective cause while the patient was still neutropenic. Two patients had Streptococcus mitis infection associated with adult respiratory distress syndrome (ARDS), another patient had ARDS associated with Eschericia coli septicemia. Four patients died from a fungal pneumonitis and one patient from C dificile colitis. All these deaths occurred in the first 21 days post-ABMT. There were seven deaths after this 3-week period. Two from transfusion-related graft-versus-host disease and the other five (four from interstitial pneumonitis and one from bowel infarction) for which no cause was found but may have been related to chemotherapy. Of the 16 deaths, 3 occurred in patients in whom postmortem examination showed failure to eradicate the disease. There were four late procedure-related deaths in patients with no evidence of disease at postmortem examination. Two patients 
Response to ABMT
At 3 months 43 (28%) patients with no abnormalities detected on CT scan were assessed as complete responders.
Seventy-two (46%) patients were assessed to have partial responses. Twenty-four patients ( 16%) showed no response or progression (Fig 1 ) . At 6 months 53 patients were assessed as complete responders. Thirteen patients deemed to be in partial remission at 3 months had achieved a CR by 6 months, this occurring in eight patients after radiotherapy to residual masses, and five patients without any further treatment indicative of slow resolution of their tumor masses. Fifty-one patients still had nonprogressive disease with persistent CT abnormalities, 26 patients had relapsed with progressive disease, and eight patients had died of progressive Hodgkin's disease. Thus, overall 104 of 155 (67%) had a "good response" to ABMT. By 6 months there were 17 procedure related deaths, those occurring at 5 months having been caused by an unexplained cardiac arrest.
Overall and Progression-Free Survival
progression-free survival of 50% (Fig 2) .
The actuarial overall survival at 5 years was 5576, with a
Patients Receiving Radiotherapy Post-ABMT
Forty-five patients received radiotherapy post-ABMT. Forty-one had either a partial or no response to BEAM and ABMT and received postgraft irradiation to residual masses if feasible in light of previous treatment with radiotherapy.
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TIME (YEARS)
Four patients achieved a complete remission with BEAM but still received radiotherapy as consolidation treatment to previous sites of bulk disease.
Ten patients received posttransplant radiotherapy to a site that was the only involved site pretransplant.
Prognostic Factors
Prognostic factors for progression-free survival were delineated using both univariate and multivariate analysis. The prognostic factors analyzed were: age, sex, histology, B symptoms at diagnosis and ABMT, length of first remission, interval between diagnosis and ABMT, stage at diagnosis and ABMT, lung involvement at ABMT, risk group A, B, or C, tumor mass at ABMT, relapse status at ABMT, and chemosensitivity status at ABMT as assessed by response to conventional dose chemotherapy at the time of relapse.
On univanate analysis, tumor mass at ABMT ( P < .001), relapse status at ABMT ( P = .001), chemosensitivity status at ABMT ( P = .001), sex ( P = .001), length from diagnosis to ABMT ( P = .001), and B symptoms at ABMT ( P = .001) were significant. There was also a trend in favor of patients with first remission lasting longer than 12 months as opposed to patients who had a first remission of less than 12 months.
On multivariate analysis, tumor mass at ABMT (P < .OO l), relapse status at ABMT ( P = .007), lines of treatment before ABMT ( P = .005), and sex ( P = .042) were significant.
It is worth noting that on univariate analysis, patients with B symptoms at ABMT, patients who proceeded to ABMT within 12 months of diagnosis, and patients with a first remission lasting less than 12 months have a poorer progressionfree survival. However, this disappeared when other factors were allowed for on multivariate analysis. Of particular note is the fact that the difference in the progression-free survival of patients between chemoresistant patients and chemosensitive patients did not achieve significance (32% v 52%; P = .37). A group of patients who had fulfilled our selection criteria but whose response to conventional therapy had not been tested at the time of latest relapse but proceeded directly to ABMT (ie, untested at relapse) had a progression-free survival at 5 years of 78%. On univariate analysis this group fared significantly better than those patients who had received some conventional salvage therapy just before ABMT (Fig  3) . Once again, this difference was not significant on multivariate analysis.
Patients with bulk disease (ie, largest tumor mass of > 10 cm) fare the worst in this group Bulk disease and ABMT. of patients, with a progression-free survival of only 13% at 5 years (Fig 4) .
Patients receiving transplants at first, second, and third relapse had progression-free survivals of 47%, 60%, and 70%, respectively. Patients with primarily refractory disease have a progression-free survival of only 33% post-ABMT. The patients receiving transplants in later relapse represent a group of patients with chronic relapsing Hodgkin's disease. The median lengths of first remission and interval from diagnosis to ABMT together with relapse status are shown in Table 2 . Patients who received a transplant in third or later relapse had a slower tempo disease with a longer median length of first remission (1 8 months) as well as interval from diagnosis to ABMT (94 months). Patients with primary refractory disease, on the other hand, obviously did not ever achieve first remission, and the median interval from initial diagnosis to ABMT was only 14 months (Fig 5) .
Fifty-two patients underwent ABMT in first relapse (30 suffering treatment failures of conventional salvage and 22 relapsing after MOPP/ABVD-type of therapy). Sixteen patients had a first remission longer than 12 months and 36 less than 12 months. The progression-free survival is 57% in the patients with longer first remission, as opposed to 41% in the patients with a remission of less than 12 months ( P = .393).
It is clear from Table  1 nificantly different outcome when compared with those patients who had received two, three, or more lines of treatment. However, multivariate analysis demonstrates that when factors such as bulk disease and relapse status are allowed for, there was a survival advantage for people who had received fewer lines of treatment before ABMT.
Males had a progressionfree survival of 56% at 5 years, which was significantly better than the females who had a progression-free survival of 34% ( P = .OO 1). On multivariate analysis the P value had decreased to .042, indicating that although gender predicts independently for outcome, the poor prognosis in females may be explained at least in part by adverse relapse status, disease bulk, and lines of prior treatment (Fig 6) .
Relapse/Progression
Overall, 30 patients have relapsed post-ABMT, after having achieved a CR or having a nonprogressive mass for at least 6 months post-ABMT. The overall relapse/progression rate at 5 years is 45%. The majority of patients relapsed within the first year. The median time to relapse post-ABMT was 9 months (5 to 67 months). There was one late relapse at 67 months post-ABMT and, apart from this patient, there have been no relapses beyond 33 months. Table 3 summarizes the relapse rate each year post-ABMT.
Ten of the patients who relapsed are alive at a median time of 14 months ( 1 to 59 months) after relapse. One patient has nonprogressive disease 27 months post-ABMT, having been treated with only six courses of vinblastine injections at the time of relapse posttransplant. The progression-free survival of the 30 patients who relapsed post-ABMT is 20% at 5 years.
Gender and response to ABMT. 
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DISCUSSION
When we embarked on the BEAM and ABMT program for relapsed and resistant Hodgkin's disease patients in 1984, few studies of the efficacy and timing of ABMT had been reported. We therefore analyzed the BNLI database of over 600 patients with advanced Hodgkin's disease in an attempt to ascertain a group of patients who would benefit from aggressive chemotherapy with its attendant risks." Various poor prognostic factors could be defined at presentation, including age, histologic subtype, stage, hemoglobin level, lymphocyte count, the ESR, and serum albumin It was not possible on the basis of presenting features to define a sizeable group of patients who would do significantly poorly to merit ABMT at presentation or in first CR. Once a CR has been obtained, the prognostic influence of presenting factors is considerably reduced. We therefore set arbitrary criteria, ie, a projected 2-year survival of < 65% and a 5-year survival of < 35%, that defined a group of poor risk patients. These criteria formed the basis for the selection of the patients reported in this study and allowed the categorization of the poor-risk groups A, B, or C. A progression-free survival of 50% and overall survival of 56% at 5 years in this group of poor-risk Hodgkin's disease patients treated with BEAM and ABMT compares favorably with a similar historical group of patients treated with conventional chemotherapy at relapse. The historical group of patients with poor-risk disease as defined by groups A, B, or C had a progression-free survival of approximately 20% at 5 years.'O Our results with BEAM and ABMT are comparable to other single-center ABMT series in which the progressionfree survival varies between 32% and 56%.26-29 However, the numbers of patients reported from single centers in these series are small. The overall procedure-related mortality with BEAM chemotherapy is IO%, which is similar to that of other regimens, such as CBV (cyclophosphamide, carmustine [BCNU] , and etoposide [VP16]) in which the dose of carmustine (BCNU) is 300 mg/m2, but may be less than the 20% mortality rate when the BCNU dose is increased to greater than 600 mg/m2.27330 All long-term survivors have a Karnofsky rating of greater than 90%. The late procedurerelated deaths include one death from acute myeloid leukemia. Another patient has myelodysplasia. The total incidence of acute myeloid leukemia/myelodysplasia in this heavily pretreated group of patients is 1.396, which is somewhat lower than expected. however, longer follow-up in these patients is needed before definitive conclusions can be drawn. With the increasing use of high-dose chemotherapy and ABMT, the consequences of such treatment will have to be carefully documented. The two successful pregnancies in premenopausal women suggests that fertility may be preserved in at least some women.
The initial assessment of response was performed at 3 months post-ABMT, and the majority of patients were assessed as partial responders on the basis of persistent CT abnormalities. The initial CR rate was only 28%, although by 6 months two thirds of the patients had achieved either a CR (53 patients) or had nonprogressive disease despite the persistent abnormalities on CT scan (5 1 patients) . The majority of the persistent masses were in the mediastinum, and this highlights the fact that residual CT abnormalities occur frequently post-ABMT, and there may be slow resolution of abnormalities. Moreover, residual masses in Hodgkin's disease, particularly in the mediastinum, may not necessarily represent residual disease.31 This means that the CR rate at 3 months should not be used to ascertain the relative efficacies of different regimens. Our study also highlights the fact that some patients with residual radiologic abnormalities may be alive and well up to 5 years post-ABMT, and therefore, progression-free survival in Hodgkin's disease is a more meaningful measurement of the efficacy of the ABMT procedure rather than disease-free survival. However, 20% of our patients who relapsed after BEAM and ABMT are still alive at 5 years from the time of relapse, and therefore, overall survival rates may overestimate the efficacy of ABMT.
Because many of the patients who relapse do so with progression of residual masses following ABMT, we have attempted to treat 45 patients with radiotherapy to sites of potential relapse or residual mass after the autograft procedure. It is difficult to determine a long-term benefit for postgraft radiotherapy for such patients, because it is difficult to find an appropriate comparison group. A comparison with a group of patients who could not receive this form of treatment because of previous radiotherapy may not be entirely valid. This is because patients who had received prior radiotherapy include a group of patients with stage I and I1 disease for which initial therapy was radiotherapy, whereas the group of patients who received radiotherapy post-ABMT had chemotherapy as first treatment and therefore presented as stage I11 and IV disease. It is our policy to continue with postgraft therapy until more meaningful conclusions can be drawn.
The main prognostic factors for survival on multivariate analysis are mass at ABMT, relapse status, lines of treatment before ABMT, and sex. It is worth noting that none of the features at presentation were significant for progression-free survival. Patients with bulky masses of greater than 10 cm at the time of ABMT have a progression-free survival of less than 20%. Females have a significantly poorer progressionfree survival in our study. We have difficulty in explaining this finding, although a similar difference is now being seen in the analysis of the European Bone Marrow Transplant group (EBMT) Registry database.32
Patients undergoing ABMT in second and third relapse are faring significantly better than patients in first relapse and primary refractory disease. At first sight the results seem contrary to expectation but reflect the disease "tempo" of the patients. The patients in late relapse possibly represent those with "chronic relapsing Hodgkin's disease," their time from diagnosis to ABMT and length of first remission is longer than for those patients in first relapse and primary refractory disease (Table 3) . It is therefore important that such patient selection is taken into account when analyzing and comparing data from different centers. Patients in first relapse include those patients who have relapsed after alternating/hybrid therapy or poor prognosis patients who relapsed after MOPPtype therapy. They also represent patients who, having relapsed after frontline chemotherapy, have experienced failure
For personal use only. on December 24, 2017. by guest www.bloodjournal.org From of one or more additional lines of treatment. It is generally accepted that patients who relapse with a first remission lasting less than 12 months have a poor prognosis. The National Cancer Institute has reported patients treated with MOPP chemotherapy who have relapsed within 12 months of achieving a CR. These patients received a variety of salvage conventional dose regimens with a progression-free survival of only 20% at 5 years and 11% at 20 years. 33 For patients who relapse early after alternating or hybrid regimens the data are sparse. The Milan group report that only 10% to 15% in early relapse after MOPP/ABVD or MOPP/ABV were salvageable after clomustine, etoposide, and p r e d m~s t i n e .~~ In our patients, those receiving BEAM and ABMT in first relapse with a first remission of less than 12 months had a progression-free survival of 4 1 % at 5 years, and this is highly encouraging, although patient selection may be a factor.
Primary refractory patients have a very poor prognosis indeed on conventional dose salvage therapy for which there is a reported long-term survival of less than 15%. 6 The progression-free survival of 33% in this group of patients undergoing ABMT suggests that dose escalation may rescue some of these patients with durable long-term survival. Patients who have chemosensitive disease have a progressionfree survival of 52% at 5 years, and so far, this is not significantly superior to the progression-free survival of 32% in chemoresistant patients. It should be noted that despite the fact that we are reporting the results of a large series of patients, the number of patients in each comparison group is small, inevitably leading to a low statistical power. Nonetheless, there can be sustained responses in patients with chemoresistant Hodgkin's disease which is in marked contrast to the situation in non-Hodgkin's lymphoma in which patients with chemoresistant disease do not show a dose-response e f f e~t .~~,~~ These results for BEAM and ABMT salvage are appreciably superior to those reported for conventional dose therapy. However, there are limitations when using historical data for comparisons. There are inevitable differences in patient selection, differences in age, length of first remission, extent of disease, and amount of presalvage therapy. It is therefore important that these encouraging results be confirmed by randomized trials. Recently, the BNLI have reported the preliminary results of a randomized trial comparing mini-BEAM (a regimen containing the same drugs as BEAM but at considerably lower doses) with BEAM and ABMT for patients with relapsed and resistant Hodgkin's disease. The patients in this trial were selected using similar criteria to the patients reported here. The disease-free survival for the mini-BEAMtreated patients reported here. The disease-free survival for the mini-BEAM-treated patients was 25%, as opposed to 62% for those receiving BEAM and ABMT (P < .05).37 Patients who may benefit from high-dose therapy in Hodgkin's disease include those with disease resistant to conventional therapy at, the time of ABMT. Patients with bulk disease at the time of relapse, those with primary refractory disease, and those who have received prior extensive therapy fare least well, and high-dose chemotherapy and ABMT alone may not be the optimal therapy.
